Direct Effects of Statins on the Vascular Wall
- 1 May 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 31 (5) , 773-778
- https://doi.org/10.1097/00005344-199805000-00017
Abstract
The beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) on coronary events have generally been attributed to their hypocholesterolemic properties. Mevalonate and other intermediates of cholesterol synthesis (isoprenoids) are necessary for cell proliferation and other important cell functions; thus effects other than cholesterol reduction may help to explain the antiatherosclerotic properties of statins. Recently we provided in vitro and in vivo evidence of decreased smooth-muscle cell (SMC) proliferation and migration by fluvastatin and simvastatin, but not by pravastatin, independent of plasma cholesterol reduction. The ability of fluvastatin to interfere with arterial SMC proliferation at therapeutic concentrations (0.1-1 μM) prompted us to investigate the pharmacologic activity of sera from 10 patients treated with fluvastatin, 40 mg once daily, on the proliferation of cultured human arterial myocytes. Pravastatin, 40 mg once daily, displays a lipid-lowering activity similar to that of fluvastatin without affecting SMC proliferation and was investigated as a control for assessing this non-lipid-related effect of fluvastatin. Fluvastatin and pravastatin, given for 6 days to patients with type IIa hypercholesterolemia, resulted in a similar decrease in low-density-lipoprotein (LDL) cholesterol. However, the addition of 15% whole-blood sera from patients treated with fluvastatin to the culture medium resulted in a 43% inhibition of cholesterol synthesis in SMCs (p < 0.01) that mirrored the pharmacokinetic profile of fluvastatin. When SMC proliferation was investigated, a significant inhibition of cell growth (−30%; p < 0.01) was detected with sera obtained 6 h after the last dose. No effect on SMC proliferation or cholesterol biosynthesis was observed when sera from patients treated with pravastatin were evaluated. These results suggest that statins exert a direct antiproliferative effect on the arterial wall, beyond their effects on plasma lipids, which could prevent significant cardiovascular disease.Keywords
This publication has 70 references indexed in Scilit:
- Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- HMG-CoA Reductase Inhibitors Reduce Acetyl LDL Endocytosis in Mouse Peritoneal MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteinsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in HumansThe Journal of Clinical Pharmacology, 1992
- Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and LovastatinThe Journal of Clinical Pharmacology, 1990
- Regulation of the mevalonate pathwayNature, 1990
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986